Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17253505 | OGA INHIBITOR COMPOUNDS | December 2020 | April 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17252613 | NLRP MODULATORS | December 2020 | May 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17251532 | GUANIDINIUM DERIVATIVES AS IMMUNITY-INDUCING AGENT | December 2020 | May 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17114473 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF ACUTE RADIATION SYNDROME AND OTHER RADIATION EXPOSURE | December 2020 | September 2022 | Allow | 21 | 2 | 1 | Yes | No |
| 17055647 | FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE | November 2020 | April 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17046633 | SMALL MOLECULE MODULATORS OF PAR2 AND USES THEREOF | October 2020 | January 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17042623 | TREATMENT AND PREVENTION OF ALPHA HERPES VIRUS INFECTION | September 2020 | July 2024 | Abandon | 46 | 4 | 0 | No | No |
| 17024149 | COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OPIOID-RECEPTOR-MEDIATED CONDITIONS | September 2020 | March 2025 | Abandon | 54 | 4 | 0 | Yes | Yes |
| 16968214 | RAPAMYCIN ANALOG FOR PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE CONDITIONS | August 2020 | August 2023 | Abandon | 36 | 2 | 0 | No | No |
| 16966079 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CHRNA6 ACTIVATORS | July 2020 | March 2023 | Abandon | 31 | 1 | 1 | No | No |
| 16963075 | THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYATION IN CANCER | July 2020 | July 2024 | Abandon | 47 | 4 | 1 | Yes | No |
| 16919677 | METHODS OF TREATING HIV | July 2020 | March 2024 | Abandon | 44 | 4 | 0 | Yes | No |
| 16958299 | COMPOSITIONS FOR TREATING INFECTIVE ARTERIAL DISEASES AND RELATED CONDITIONS | June 2020 | May 2024 | Abandon | 46 | 2 | 0 | No | Yes |
| 16910392 | COMPOSITION COMPRISING FARNESOL AND USE THEREOF | June 2020 | January 2023 | Abandon | 31 | 2 | 1 | No | No |
| 16957490 | COMPOSITION FOR INHIBITING REACTIVE OXYGEN SPECIES PRODUCTION | June 2020 | June 2023 | Abandon | 36 | 2 | 1 | No | No |
| 16956740 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA | June 2020 | June 2023 | Abandon | 36 | 2 | 1 | Yes | No |
| 16902730 | OXYSTEROLS AND METHODS OF USE THEREOF | June 2020 | June 2023 | Abandon | 36 | 2 | 1 | No | No |
| 16767121 | METHOD FOR PREDICTING AND MODULATING SUSCEPTIBILITY OF CANCER CELL TO PROGRAMMED CELL DEATH | May 2020 | July 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16763498 | STEROIDAL COMPOUNDS FOR TREATMENT OF MENTAL AND NEUROLOGICAL DISORDERS | May 2020 | April 2023 | Abandon | 35 | 2 | 1 | Yes | No |
| 16652723 | Viral Inhibitor | April 2020 | May 2024 | Abandon | 49 | 5 | 0 | No | No |
| 16821365 | AUTOTAXIN INHIBITORS AND USES THEREOF | March 2020 | June 2025 | Allow | 60 | 6 | 0 | No | Yes |
| 16633242 | METHODS OF TREATING INFLUENZA-ASSOCIATED VIRAL PNEUMONIA | January 2020 | March 2024 | Abandon | 50 | 2 | 0 | No | Yes |
| 16736095 | COMPOSITIONS AND METHODS FOR ENHANCING SEXUAL PLEASURE AND PERFORMANCE | January 2020 | March 2025 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 16727577 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | December 2019 | August 2023 | Abandon | 44 | 3 | 1 | No | No |
| 16694197 | WATER SOLUBLE FORMULATION FOR PHARMACEUTICAL AND NUTRACEUTICAL COMPOUNDS AND METHOD OF PREPARING THEREOF | November 2019 | May 2021 | Abandon | 17 | 2 | 1 | No | No |
| 16615485 | Composition for Improving Brain Function | November 2019 | March 2023 | Abandon | 39 | 2 | 1 | Yes | No |
| 16607353 | Method for Inhibiting Both Glycolysis and Glutamine Metabolism in Cells and Use Thereof | October 2019 | December 2022 | Abandon | 38 | 2 | 1 | No | No |
| 16584626 | ALTERING EXPRESSION LEVEL OF GLUTATHIONE S-TRANSFERASE GENES BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | September 2019 | August 2024 | Abandon | 58 | 6 | 1 | Yes | No |
| 16403288 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | May 2019 | January 2020 | Allow | 8 | 4 | 0 | Yes | Yes |
| 16341476 | COMPOSITION FOR PREVENTING OR TREATING HEPATITIS CONTAINING MONOACETYL DIACYLGLYCEROL COMPOUND | April 2019 | May 2023 | Abandon | 49 | 3 | 1 | No | Yes |
| 16331407 | COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERS | March 2019 | March 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16325867 | USE OF BCL-XL INHIBITOR AND ONCOLYTIC VIRUS IN PREPARATION OF ANTITUMOR DRUG | February 2019 | December 2022 | Abandon | 46 | 0 | 1 | No | No |
| 16501039 | Methods and compositions for the treatment of diverticulosis | February 2019 | December 2021 | Allow | 34 | 2 | 1 | Yes | No |
| 16314851 | Use of Scavengers of Reactive Gamma-Ketoaldehydes to Extend Cell Lifespan and Healthspan | January 2019 | November 2022 | Allow | 60 | 3 | 1 | No | Yes |
| 16225672 | CHROMOPHORE COMBINATIONS FOR BIOPHOTONIC USES | December 2018 | June 2023 | Abandon | 54 | 5 | 1 | Yes | No |
| 16220890 | Nutraceutical Compositions Comprising C60 and Cox-2 Inhibitor | December 2018 | September 2021 | Allow | 33 | 5 | 1 | No | No |
| 16215854 | PESTICIDE COMPOSITION COMPRISING A TETRAZOLYLOXIME DERIVATIVE AND A FUNGICIDE OR AN INSECTICIDE ACTIVE SUBSTANCE | December 2018 | August 2021 | Allow | 32 | 1 | 1 | No | No |
| 16309026 | COMPOSITIONS AND METHODS FOR MODELING HEART FAILURE WITH PRESERVED EJECTION FRACTION | December 2018 | January 2023 | Abandon | 49 | 0 | 1 | No | No |
| 16095224 | USE OF THYROID BETA-AGONISTS | October 2018 | January 2022 | Abandon | 39 | 2 | 1 | No | No |
| 16138028 | AGENT CONTAINING FAT (OIL), WHICH CONTAINS ONION EXTRACT, THE PRODUCTION AND USE THEREOF FOR CARING, PREVENTING OR TREATING DAMAGED SKIN TISSUE, ESPECIALLY SCARRED TISSUE | September 2018 | February 2022 | Abandon | 41 | 2 | 1 | No | No |
| 16062946 | PHOSPHONIC ETHYLENIC POLYMER AND COSMETIC USES THEREOF | June 2018 | August 2021 | Allow | 39 | 1 | 1 | Yes | No |
| 15756286 | SOLID SOLUBLE FERRIC PYROPHOSPHATE FORMULATIONS, KITS, AND METHODS USING THE SAME | February 2018 | June 2022 | Allow | 52 | 4 | 1 | Yes | Yes |
| 15748880 | METHOD AND COMPOSITION | January 2018 | March 2023 | Abandon | 60 | 6 | 1 | Yes | No |
| 15748625 | METHODS OF TREATING ACNE USING NANOEMULSION COMPOSITIONS | January 2018 | April 2023 | Abandon | 60 | 6 | 1 | Yes | No |
| 15746996 | ANTIMICROBIAL COMPOSITIONS FOR SURGICAL APPLICATIONS | January 2018 | July 2022 | Abandon | 54 | 4 | 1 | No | No |
| 15745490 | THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF CANCER | January 2018 | November 2022 | Abandon | 58 | 4 | 1 | Yes | No |
| 15856853 | COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN | December 2017 | January 2023 | Abandon | 60 | 4 | 1 | No | Yes |
| 15736550 | COMBINATION THERAPY USING BELINOSTAT AND PRALATREXATE TO TREAT LYMPHOMA | December 2017 | May 2022 | Allow | 53 | 4 | 1 | Yes | No |
| 15579007 | METHODS OF DIAGNOSING AND TREATING CANCER | December 2017 | February 2022 | Abandon | 50 | 3 | 1 | No | No |
| 15577625 | METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS | November 2017 | December 2022 | Abandon | 60 | 4 | 1 | Yes | No |
| 15564088 | METHODS AND COMPOSITIONS FOR TREATING GASTRIC ULCERS | October 2017 | January 2022 | Allow | 51 | 5 | 1 | Yes | No |
| 15668542 | NOVEL ANTI-INFLAMMATORY AGENTS | August 2017 | March 2023 | Abandon | 60 | 6 | 1 | No | No |
| 15655712 | SMALL MOLECULE OXIDIZERS OF PDI AND THEIR USE | July 2017 | January 2023 | Abandon | 60 | 6 | 1 | Yes | No |
| 15538569 | PROSTAGLANDIN TRANSPORTER INHIBITORS FOR INHIBITING OVULATION | June 2017 | April 2022 | Abandon | 58 | 5 | 1 | Yes | No |
| 15534625 | COMPOSITION FOR ACTIVATING LONGEVITY GENE | June 2017 | December 2022 | Abandon | 60 | 7 | 1 | No | No |
| 15611551 | METHODS OF TREATMENT OF ACNE VULGARIS USING TOPICAL DAPSONE COMPOSITIONS | June 2017 | May 2024 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 15490532 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | April 2017 | April 2022 | Abandon | 60 | 4 | 1 | No | No |
| 15517581 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS | April 2017 | December 2021 | Allow | 56 | 4 | 1 | Yes | No |
| 15306981 | METHODS OF REDUCING DECLINE IN VITAL CAPACITY | October 2016 | April 2023 | Abandon | 60 | 7 | 1 | Yes | No |
| 13387971 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | March 2012 | October 2022 | Allow | 60 | 9 | 1 | Yes | Yes |
| 13377131 | COMPOSITIONS FOR ATTRACTING BLOOD-FEEDING INSECTS | December 2011 | February 2014 | Allow | 27 | 1 | 1 | No | No |
| 12309091 | POLYSILOXANE ANTIMICROBIALS | January 2011 | October 2013 | Allow | 60 | 1 | 1 | Yes | No |
| 12871392 | SYNERGISTIC FUNGICIDAL COMPOSITIONS CONTAINING A 5-FLUOROPYRIMIDINE DERIVATIVE FOR FUNGAL CONTROL IN CEREALS | August 2010 | February 2013 | Allow | 30 | 1 | 1 | No | No |
| 12373559 | PYRIMIDINE DERIVATIVES AND THEIR USE AS PESTICIDES | August 2009 | August 2012 | Allow | 43 | 2 | 1 | Yes | No |
| 12186555 | PIPERAZINE AMIDE DERIVATIVES | August 2008 | June 2012 | Allow | 46 | 2 | 1 | Yes | No |
| 11666988 | 2-ALKOXY-6-ALKYL-PHENYL-SUBSTITUTED SPIROCYCLIC TETRAMIC ACID DERIVATIVES | November 2007 | December 2009 | Allow | 32 | 1 | 1 | No | No |
| 10588862 | TETRAHYDROBENZO(D)AZEPIN-2-ONE DERIVATIVES AND THE USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | June 2007 | May 2009 | Allow | 33 | 1 | 1 | Yes | No |
| 11806461 | Benzamide derivatives and uses related thereto | May 2007 | February 2014 | Allow | 60 | 4 | 1 | Yes | No |
| 11806480 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | May 2007 | September 2009 | Allow | 27 | 1 | 1 | Yes | No |
| 11661284 | 2-PHENYLPYRIDINE DERIVATIVE | February 2007 | June 2010 | Allow | 39 | 0 | 1 | Yes | No |
| 11660907 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | February 2007 | April 2012 | Allow | 60 | 3 | 1 | No | No |
| 11630569 | 2-SUBSTITUTED PYRIDINES, PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING HARMFUL FUNGI | December 2006 | November 2009 | Allow | 35 | 2 | 1 | Yes | No |
| 11609854 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | December 2006 | September 2009 | Allow | 33 | 2 | 1 | No | No |
| 11609858 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | December 2006 | May 2009 | Allow | 29 | 1 | 1 | No | No |
| 10568993 | PESTICIDALLY ACTIVE PHENOL DERIVATIVES | November 2006 | August 2009 | Allow | 41 | 0 | 0 | No | No |
| 11462228 | AN ANTIMICROBIAL COMPOSITION FOR TOPICAL APPLICATION AND A METHOD THEREOF | August 2006 | October 2010 | Allow | 51 | 2 | 1 | No | No |
| 10579562 | VITAMIN D RECEPTOR MODULATORS | May 2006 | July 2009 | Allow | 39 | 1 | 1 | Yes | No |
| 10786881 | 9-AMINOMETHYL SUBSTITUTED MINOCYCLINE COMPOUNDS | February 2004 | March 2009 | Allow | 60 | 4 | 1 | Yes | Yes |
| 10697655 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME | October 2003 | December 2008 | Allow | 60 | 1 | 1 | Yes | No |
| 10240413 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENICS AGENTS | October 2002 | June 2010 | Allow | 60 | 8 | 0 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KLINKEL, KORTNEY L.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 5.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KLINKEL, KORTNEY L works in Art Unit 1627 and has examined 80 patent applications in our dataset. With an allowance rate of 42.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner KLINKEL, KORTNEY L's allowance rate of 42.5% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KLINKEL, KORTNEY L receive 2.98 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KLINKEL, KORTNEY L is 46 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +24.3% benefit to allowance rate for applications examined by KLINKEL, KORTNEY L. This interview benefit is in the 69% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 12.6% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 17.1% of cases where such amendments are filed. This entry rate is in the 21% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 53% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 58.3% of appeals filed. This is in the 33% percentile among all examiners. Of these withdrawals, 71.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 44.0% are granted (fully or in part). This grant rate is in the 35% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 8.8% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 11.8% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.